Hao Dawei, Sun Lingfei, Hu Xiang, Hao Xiaowen
Department of Radiotherapy, Xuzhou Central Hospital, Xuzhou, Jiangsu 221009, P.R. China.
Oncol Lett. 2017 Jul;14(1):569-578. doi: 10.3892/ol.2017.6246. Epub 2017 May 24.
Detection of gonadotropin-releasing hormone (GnRH) also known as luteinizing hormone-releasing hormone (LHRH) in the relevant tumor tissue and normal tissues and organs expression was investigated. To examine the method of direct radio labeling of LHRH by Tc with relatively high radiochemical purity and stability, screening the best labeling conditions, to establish a simple and reliable method of preparation of Tc-LHRH was undertaken. The detection of radioisotope-labeled LHRH distribution in mice, LHRH receptor imaging for the study and treatment of cancer basis were evaluated. i) Immunohistochemical staining test was used in 23 patients with hepatocellular carcinoma (HCC), 20 patients with breast cancer, 10 patients with prostate cancer, 20 patients with lung cancer, 20 patients with endometrial cancer tumor cells and normal tissue LHRH-R De Biaoda levels; ii) pre-tin method use direct labeling of LHRH, marking completion of saline or human serum were added at room temperature, the chromatography was measured at different times, to calculate the rate of labeled product and the radiochemical purity of the label, observation of its stability, and comparative analysis of selected optimal condition; iii) rat pituitary cell membrane protein, the product of radio-receptor marker analysis, through the saturation and inhibition experiments, was used to test its receptor binding activity; iv) Ch-T method labeled I-LHRH, tail vein injection of normal mice at different times were sacrificed, blood and major organs were determined and calculated per gram organization percentage injected dose rate (%, ID/g). Detected by immunohistochemistry in 23 cases of HCC in the LHRH-positive rate was 82.61%, in the corresponding normal tissues, the positive rate was 15%; 20 cases of breast cancer positive rate of 95%, the corresponding normal tissues, the positive rate was 20%; 10 cases of prostate cancer positive rate of 70%, the corresponding normal tissues, the positive rate of 40%; 20 cases of lung cancer positive rate of 85%, the corresponding normal tissues, the positive rate of 15.79%; 20 cases of endometrial cancer positive rate of 80% in the corresponding normal tissues was 16.67% positive. Tc-LHRH mark was 97.9-100.0%, the radiochemical purity of 93.9-96.4%, marking the reaction gel content of <5%. Great product receptor marker analysis showed Tc-LHRH with saturable receptor binding characteristics and inhibition, and high affinity, RT = 23.2174 pmol, KD = 0.4348 nmol; intravenous injection of I-LHRH within 72 h after the mice rapidly cleared the blood radioactivity, the major radioactive accumulation in the liver and kidneys and by the liver, renal clearance, and other tissues and organs of the radioactivity gradually decreased with time. In conclusion, i) the liver, lung, breast, prostate, endometrial cancer exist in both LHRHR; ii) Tc-LHRH preparation is simple, rapid, radiochemical purity product obtained higher marks, better stability, no further purification; and iii) LHRH Tc labeled, still has a high receptor binding ability, biological activity; and has an ideal and realistic dynamics in animals, there is hope, as with the clinical value of imaging agent of GnRH receptors.
研究了促性腺激素释放激素(GnRH)又称促黄体生成素释放激素(LHRH)在相关肿瘤组织及正常组织和器官中的表达情况。为研究用锝直接放射性标记LHRH的方法,该方法具有较高的放射化学纯度和稳定性,筛选最佳标记条件,建立一种简单可靠的锝- LHRH制备方法。评估放射性同位素标记的LHRH在小鼠体内的分布检测情况,为研究和治疗癌症的LHRH受体显像奠定基础。i)采用免疫组化染色检测23例肝细胞癌(HCC)、20例乳腺癌、10例前列腺癌、20例肺癌、20例子宫内膜癌患者肿瘤细胞及正常组织中LHRH-R的表达水平;ii)采用预锡法直接标记LHRH,标记完成后于室温下加入生理盐水或人血清,在不同时间进行层析测定,计算标记产物的标记率和放射化学纯度,观察其稳定性,并进行比较分析以选择最佳条件;iii)用大鼠垂体细胞膜蛋白进行放射受体标记分析产物,通过饱和及抑制实验检测其受体结合活性;iv)采用Ch-T法标记I-LHRH,尾静脉注射正常小鼠后在不同时间处死,测定血液及主要脏器放射性,并计算每克组织注射剂量率(%,ID/g)。免疫组化检测显示,23例HCC中LHRH阳性率为82.61%,相应正常组织中阳性率为15%;20例乳腺癌阳性率为95%,相应正常组织中阳性率为20%;10例前列腺癌阳性率为70%,相应正常组织中阳性率为40%;20例肺癌阳性率为85%,相应正常组织中阳性率为15.79%;20例子宫内膜癌阳性率为80%,相应正常组织中阳性率为16.67%。锝- LHRH标记率为97.9 - 100.0%,放射化学纯度为93.9 - 96.4%,标记反应凝胶含量<5%。放射受体标记分析显示锝- LHRH具有可饱和的受体结合特性及抑制作用,且亲和力高,RT = 23.2174 pmol,KD = 0.4348 nmol;静脉注射I-LHRH后72 h内小鼠血液放射性迅速清除,主要放射性积聚于肝脏和肾脏并经肝、肾清除,其他组织器官放射性随时间逐渐降低。综上所述,i)肝癌、肺癌、乳腺癌、前列腺癌、子宫内膜癌组织中均存在LHRHR;ii)锝- LHRH制备方法简单、快速,所得标记产物放射化学纯度较高,稳定性较好,无需进一步纯化;iii)锝标记的LHRH仍具有较高的受体结合能力和生物活性;且在动物体内具有理想的动力学表现,有望作为GnRH受体显像剂应用于临床。